Identification of new epilepsy treatments: Issues in preclinical methodology

Aristea S. Galanopoulou, Paul S. Buckmaster, Kevin J. Staley, Solomon L. Moshe, Emilio Perucca, Jerome Engel, Wolfgang Löscher, Jeffrey L. Noebels, Asla Pitkänen, James Stables, H. Steve White, Terence J. O'Brien, Michele Simonato

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for: (1) new symptomatic antiseizure treatments for drug-resistant seizures with improved efficacy/tolerability profiles, (2) disease-modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age- or gender-specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.

Original languageEnglish (US)
Pages (from-to)571-582
Number of pages12
JournalEpilepsia
Volume53
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Epilepsy
Comorbidity
Seizures
Therapeutics
Drug Discovery
Drug Delivery Systems
Disabled Persons
Research Design
Quality of Life
Guidelines
Research
Pharmaceutical Preparations

Keywords

  • Antiepileptogenesis
  • Antiseizure drug
  • Biomarkers
  • Comorbidities
  • Disease modification

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Identification of new epilepsy treatments : Issues in preclinical methodology. / Galanopoulou, Aristea S.; Buckmaster, Paul S.; Staley, Kevin J.; Moshe, Solomon L.; Perucca, Emilio; Engel, Jerome; Löscher, Wolfgang; Noebels, Jeffrey L.; Pitkänen, Asla; Stables, James; White, H. Steve; O'Brien, Terence J.; Simonato, Michele.

In: Epilepsia, Vol. 53, No. 3, 03.2012, p. 571-582.

Research output: Contribution to journalArticle

Galanopoulou, AS, Buckmaster, PS, Staley, KJ, Moshe, SL, Perucca, E, Engel, J, Löscher, W, Noebels, JL, Pitkänen, A, Stables, J, White, HS, O'Brien, TJ & Simonato, M 2012, 'Identification of new epilepsy treatments: Issues in preclinical methodology', Epilepsia, vol. 53, no. 3, pp. 571-582. https://doi.org/10.1111/j.1528-1167.2011.03391.x
Galanopoulou, Aristea S. ; Buckmaster, Paul S. ; Staley, Kevin J. ; Moshe, Solomon L. ; Perucca, Emilio ; Engel, Jerome ; Löscher, Wolfgang ; Noebels, Jeffrey L. ; Pitkänen, Asla ; Stables, James ; White, H. Steve ; O'Brien, Terence J. ; Simonato, Michele. / Identification of new epilepsy treatments : Issues in preclinical methodology. In: Epilepsia. 2012 ; Vol. 53, No. 3. pp. 571-582.
@article{20be7a90dbaf4fe5a074a0869c719d11,
title = "Identification of new epilepsy treatments: Issues in preclinical methodology",
abstract = "Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for: (1) new symptomatic antiseizure treatments for drug-resistant seizures with improved efficacy/tolerability profiles, (2) disease-modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age- or gender-specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.",
keywords = "Antiepileptogenesis, Antiseizure drug, Biomarkers, Comorbidities, Disease modification",
author = "Galanopoulou, {Aristea S.} and Buckmaster, {Paul S.} and Staley, {Kevin J.} and Moshe, {Solomon L.} and Emilio Perucca and Jerome Engel and Wolfgang L{\"o}scher and Noebels, {Jeffrey L.} and Asla Pitk{\"a}nen and James Stables and White, {H. Steve} and O'Brien, {Terence J.} and Michele Simonato",
year = "2012",
month = "3",
doi = "10.1111/j.1528-1167.2011.03391.x",
language = "English (US)",
volume = "53",
pages = "571--582",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Identification of new epilepsy treatments

T2 - Issues in preclinical methodology

AU - Galanopoulou, Aristea S.

AU - Buckmaster, Paul S.

AU - Staley, Kevin J.

AU - Moshe, Solomon L.

AU - Perucca, Emilio

AU - Engel, Jerome

AU - Löscher, Wolfgang

AU - Noebels, Jeffrey L.

AU - Pitkänen, Asla

AU - Stables, James

AU - White, H. Steve

AU - O'Brien, Terence J.

AU - Simonato, Michele

PY - 2012/3

Y1 - 2012/3

N2 - Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for: (1) new symptomatic antiseizure treatments for drug-resistant seizures with improved efficacy/tolerability profiles, (2) disease-modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age- or gender-specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.

AB - Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for: (1) new symptomatic antiseizure treatments for drug-resistant seizures with improved efficacy/tolerability profiles, (2) disease-modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age- or gender-specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.

KW - Antiepileptogenesis

KW - Antiseizure drug

KW - Biomarkers

KW - Comorbidities

KW - Disease modification

UR - http://www.scopus.com/inward/record.url?scp=84857648355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857648355&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2011.03391.x

DO - 10.1111/j.1528-1167.2011.03391.x

M3 - Article

C2 - 22292566

AN - SCOPUS:84857648355

VL - 53

SP - 571

EP - 582

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 3

ER -